TRAD CHI MED (00570) announced its annual results for the period ending December 31, 2025. The group's revenue was RMB 147.45 billion, a decrease of 10.7% compared to the previous year. The company reported a net loss of RMB 458 million, a swing from profit to loss year-on-year. The basic loss per share was 6.79 cents.

According to the announcement, the loss during the period was primarily due to a decline in revenue scale and profitability in the traditional Chinese medicine formula granules business. This was impacted by factors such as an increased proportion of volume-based procurement business and intensified market competition. Additionally, there was an increase in impairments for goodwill, intangible assets, and credit losses during the period.